SBIR/STTR Research Award
SBIR Phase I: Enhancing the Efficacy of a Novel Cancer Drug through Combinatorial Chemistry
Award amount
$99,927Program and phase
SBIR · Phase IAward year
2004Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- LUNA INNOVATIONS INCORPORATED
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- SJHFCDGKJJC5
- Solicitation number
- Not reported
- Topic code
- Not reported
Research abstract
This Small Business Innovation Research Phase I project proposes to enhance the efficacy of a new anti-cancer drug, based on a novel lead molecule, through combinatorial chemistry. Preliminary data have shown that this drug, in higher doses, has the ability to kill cancerous cells while leaving non-cancerous cells unaffected. The commercial application of this project will be in the area of anti-cancer therapeutics for treatment of breast cancer.
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Rugged Miniature SWDM Mux and Demux for Military Aircraft
- Advanced Distributed Fiber Optic Sensing (DFOS) for Naval Safety
- Distributed Linear and Angular Acceleration Measurement
- Terahertz Imaging for Detection of Corrosion and Defects Under Hull Coatings
- Multi-Modal SHM of Inflatable Habitats via Embedded Fiber Optics Sensing
Research funding history
994 SBIR/STTR records share this UEI (1991–2026). Reported award amounts total $336,438,763. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Defense, National Aeronautics and Space Administration, Department of Energy, Department of Health and Human Services, National Science Foundation, Environmental Protection Agency